Affinage

CEACAM5

Cell adhesion molecule CEACAM5 · UniProt P06731

Length
702 aa
Mass
76.8 kDa
Annotated
2026-06-09
74 papers in source corpus 22 papers cited in narrative 22 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CEACAM5 is a GPI-anchored, heavily glycosylated cell-surface glycoprotein that functions as an adhesion molecule and signaling ligand on epithelial and tumor cells, with major roles in tumor progression, immune modulation, and as a receptor for bacterial pathogens (PMID:12813580, PMID:31928422, PMID:10816511). Its expression is controlled at multiple levels: by Smad3-mediated TGF-β signaling, which induces CEACAM5 and is required for normal CEA expression in vivo (PMID:17653079); by HIF1α acting as a direct transcriptional activator downstream of FBW7 (PMID:29910683); by ASCL1-driven increases in chromatin accessibility at the core promoter during neuroendocrine reprogramming (PMID:33199493); and by promoter CpG hypomethylation, which derepresses CEA expression in colorectal cancer (PMID:37942534). The membrane-anchored (not secreted) form specifically supports primary tumor growth, and domain-specific antibody Fabs targeting the N-terminal/A1B1 and A3B3 domains block tumor cell migration, ECM invasion, and endothelial adhesion (PMID:12813580, PMID:16204051). On tumor cells, CEACAM5 engages the inhibitory receptor CEACAM1 on NK cells as an immune checkpoint, and antibody blockade of this heterophilic interaction restores NK cytotoxicity (PMID:31928422, PMID:21731662). On intestinal epithelium, CEACAM5 binds CD8α through its glycosylated N-domain and CD1d through its B3 domain to activate CD8+ suppressor T cells (PMID:24104458). CEACAM5 serves as a host receptor for multiple bacteria, mediating Afa/Dr DAEC adhesion via receptor clustering (PMID:10816511), H. pylori CagA T4SS delivery (PMID:30321907), and F. nucleatum CbpF binding through the conserved Q78 residue in a multivalent Velcro-like mode (PMID:40928870). Tumor-associated CEACAM5 carries distinctive glycans—Lewis X/Y, branched N-glycans, and mannose—that confer recognition by the C-type lectin DC-SIGN (PMID:21823122), and its A3-B3 domains form a discontinuous, glycan-containing epitope (N-linked mannose at Asn612) targeted by therapeutic antibodies (PMID:39477960).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 2000 High

    Established that CEACAM5 acts as a functional surface receptor for enteric bacteria, not merely a passive adhesion antigen, by showing it is clustered around and required for Afa/Dr DAEC adhesion.

    Evidence Stable CD66e transfection of HeLa cells, antibody blocking, and immunofluorescence of receptor clustering in polarized Caco-2/TC7 cells

    PMID:10816511

    Open questions at the time
    • Did not define the CEACAM5 domain or glycan determinants of bacterial binding
    • Signaling consequences of clustering not characterized
  2. 2005 Medium

    Distinguished the membrane-anchored form of CEACAM5 as the species driving primary tumor growth, addressing whether secreted versus surface CEA mediates the oncogenic phenotype.

    Evidence Antisense knockdown and xenograft tumor formation in nude mice with subclones producing membrane-bound versus secreted CEACAM5

    PMID:12813580

    Open questions at the time
    • Molecular mechanism by which membrane CEACAM5 promotes growth not defined
    • Single cell line/lab
  3. 2005 Medium

    Mapped which CEACAM5 domains mediate distinct adhesive/invasive functions, showing N-terminal/A1B1 epitopes govern migration and ECM invasion while A3B3 governs endothelial adhesion.

    Evidence Domain-specific antibody Fabs (MN-3, MN-15, MN-14) in migration, invasion, adhesion assays and an in vivo micrometastasis model

    PMID:16204051

    Open questions at the time
    • Did not identify the counter-receptors engaged by each domain
    • Antibody Fabs may have steric effects beyond their target epitope
  4. 2007 High

    Identified TGF-β/Smad3 as a direct transcriptional driver of CEACAM5, providing the first upstream regulatory pathway.

    Evidence Promoter-luciferase assays, TβRII/Smad3 rescue in unresponsive gastric cancer lines, and Smad3-null mice

    PMID:17653079

    Open questions at the time
    • Direct Smad3 binding site on the promoter not delineated
    • Relationship to other regulators not addressed
  5. 2011 Medium

    Demonstrated the CEACAM5/CEACAM1 heterophilic interaction is an NK-cell inhibitory checkpoint that can be relieved by antibody blockade, framing CEACAM5 as an immune evasion ligand.

    Evidence In vitro NK cytotoxicity assays against MHC-I-deficient CRC cells with anti-CEACAM5 antibody CC4 blocking

    PMID:21731662

    Open questions at the time
    • In vitro only; no in vivo confirmation
    • Binding interface between CEACAM5 and CEACAM1 not structurally defined
  6. 2011 Medium

    Showed that tumor-specific glycan remodeling of CEACAM5 creates lectin-recognition determinants, linking aberrant glycosylation to immune recognition.

    Evidence Lectin capture ELISA (DC-SIGN, MGL, Galectin-3) on CEACAM5 from matched normal versus tumor CRC tissue from 48 patients

    PMID:21823122

    Open questions at the time
    • Functional consequence of DC-SIGN recognition on APC behavior not tested
    • Glycan structures inferred from lectin binding rather than directly resolved
  7. 2013 Medium

    Defined the domain and glycan requirements for CEACAM5 engagement of CD8α and CD1d, establishing it as an activating ligand for suppressor CD8+ T cells in the intestine.

    Evidence Co-IP, domain deletion mutants, Lck activation assay, and in vitro T cell suppression assays with IL-15/IL-7

    PMID:24104458

    Open questions at the time
    • In vivo relevance of CD8+ suppressor induction not established
    • Single lab
  8. 2018 Medium

    Placed CEACAM5 within the FBW7–HIF1α axis as a direct hypoxia-responsive target gene controlling colorectal cancer cell migration.

    Evidence Luciferase reporter and ChIP assays, ectopic FBW7 expression with CEACAM5 silencing and migration assays

    PMID:29910683

    Open questions at the time
    • HIF1α binding site coordinates not finely mapped
    • Connection to other CEACAM5 regulators unresolved
  9. 2018 Medium

    Showed CEACAM5 can promote metastatic outgrowth by driving mesenchymal-to-epithelial transition, contrasting with anti-metastatic roles reported in other cancers.

    Evidence Serial in vivo metastasis passaging, in vivo gain-of-function screen, transcriptomics, and patient IHC (inverse CEACAM5/vimentin correlation)

    PMID:29736411

    Open questions at the time
    • Molecular mechanism linking CEACAM5 to the epithelial program not defined
    • Apparent context-dependent opposite effects on EMT across tumor types unreconciled
  10. 2018 High

    Established CEACAM5 as an essential host receptor for H. pylori T4SS effector delivery, extending its receptor function to a second pathogen system.

    Evidence Genetic introduction of CEACAM1/5/6 into T4SS-deficient AZ-521 cells with CagA phosphorylation and vinculin/cortactin dephosphorylation readouts

    PMID:30321907

    Open questions at the time
    • Direct bacterial adhesin–CEACAM5 contact residues not mapped in this study
    • Mechanism of T4SS coupling to CEACAM5 unresolved
  11. 2020 Medium

    Identified ASCL1-driven chromatin remodeling at the CEACAM5 promoter as the mechanism elevating CEACAM5 during neuroendocrine transdifferentiation, expanding regulation to a lineage-plasticity context.

    Evidence Genetically defined neuroendocrine transdifferentiation assay with chromatin accessibility profiling

    PMID:33199493

    Open questions at the time
    • Direct ASCL1 occupancy at the promoter not shown
    • Functional role of elevated CEACAM5 in neuroendocrine cells untested
  12. 2020 Medium

    Reinforced the CEACAM5/CEACAM1 NK checkpoint mechanism using a distinct blocking antibody, supporting therapeutic targeting of the interaction.

    Evidence In vitro NK-92 cytotoxicity assays with NEO-201 antibody blockade against CEACAM5+ tumor lines

    PMID:31928422

    Open questions at the time
    • NK-92 lacks ADCC, so only direct inhibition tested
    • In vivo efficacy not addressed
  13. 2023 Medium

    Identified promoter hypomethylation as a major epigenetic switch controlling CEA expression and serum CEA levels in colorectal cancer.

    Evidence 5-aza-2'-deoxycytidine demethylation in HCT116/HT29 cells, bisulfite CpG mapping, and serum CEA correlation in CRC patients

    PMID:37942534

    Open questions at the time
    • Causal demethylation at specific mapped CpGs not directly tested
    • Interplay with TGF-β/HIF1α regulation not integrated
  14. 2024 High

    Resolved the structural basis of therapeutic antibody recognition, defining a discontinuous A3-B3 glycoepitope including N-linked mannose at Asn612.

    Evidence 3.11 Å cryo-EM of CEACAM5 A3-B3/tusamitamab Fab, HDX-MS paratope mapping, and SPR alanine mutagenesis

    PMID:39477960

    Open questions at the time
    • Structure limited to A3-B3 fragment, not full-length CEACAM5
    • Does not address heterophilic counter-receptor interfaces
  15. 2025 High

    Provided atomic detail of a third pathogen interaction, defining the F. nucleatum CbpF–CEACAM5 interface and a multivalent Velcro-like adhesion mechanism.

    Evidence Structural determination of CbpF–CEACAM1/CEACAM5 complex with mutagenesis of the EFNGQYQ loop and CEACAM5 Q78

    PMID:40928870

    Open questions at the time
    • Cellular consequences of multivalent engagement not functionally assayed here
    • Affinity contributions of individual contacts not quantified
  16. 2035 Medium

    Showed that surface accessibility of CEACAM5, governed by junctional sequestration and glycocalyx, is a rate-limiting determinant of anti-CEACAM5 CAR T cell activation.

    Evidence Live-cell calcium imaging, CEACAM5 localization microscopy, and trypsin/hyaluronidase rescue with cytotoxicity and TNF-α readouts in CRC monolayers

    PMID:41572139

    Open questions at the time
    • Mechanism of junctional CEACAM5 sequestration not molecularly defined
    • Single-lab model system

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how the diverse, context-dependent CEACAM5 phenotypes (pro- versus anti-metastatic, immune-suppressive versus inflammatory) are integrated through a unified downstream signaling logic.
  • No defined cytoplasmic signaling output for a GPI-anchored protein
  • Counter-receptor stoichiometry and downstream effectors largely uncharacterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0001618 virus receptor activity 3 GO:0048018 receptor ligand activity 3 GO:0098631 cell adhesion mediator activity 2
Localization
GO:0005886 plasma membrane 3
Pathway
R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1643685 Disease 3 R-HSA-168256 Immune System 3
Partners
CD1DCD8ACEACAM1LGALS3LGALS9

Evidence

Reading pass · 22 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2013 CEACAM5 binds CD8α through its N-domain (glycosylated residues required) and interacts with CD1d through its B3 domain; CEACAM5-activated CD8+ T cells acquire the ability to suppress CD4+ T cell proliferation in vitro in the presence of IL-15 or IL-7, and removal of N-domain glycosylated residues reduces CD8α binding affinity and Lck activation. Co-IP, domain deletion mutants, antibody blocking, Lck activation assay, in vitro T cell suppression assay Mucosal immunology Medium 24104458
2007 CEACAM5 (and CEACAM6) expression is transcriptionally driven by Smad3-mediated TGF-β signaling; restoration of TGF-β signaling in TGF-β-unresponsive gastric cancer cell lines (via re-expression of TβRII or Smad3) induced CEACAM5/CEACAM6 expression and activated their promoters. CEA expression was markedly decreased in Smad3 null mice. Promoter-luciferase assay, rescue expression of TβRII/Smad3 in mutant cell lines, Smad3 knockout mouse model, RT-PCR/Western blot Oncogene High 17653079
2000 CEACAM5 (CD66e) is recruited and clustered around adhering Afa/Dr DAEC bacteria on polarized intestinal Caco-2/TC7 cells, and functions as a receptor for these bacteria; HeLa cells stably expressing CD66e supported efficient Afa/Dr DAEC binding with CD66e clustering; antibody blocking with anti-CD66e antibodies inhibited bacterial adhesion. Stable transfection of HeLa cells with CD66e, antibody inhibition assays, immunofluorescence of receptor clustering, structural draE gene mutants Infection and immunity High 10816511
2018 CEACAM5 expression is sufficient to rescue T4SS-dependent CagA injection and phosphorylation by Helicobacter pylori in T4SS-deficient AZ-521 cells; CEACAM1 or CEACAM5 (but not CEACAM6) expression restored CagA translocation, and expression was also accompanied by tyrosine dephosphorylation of vinculin and cortactin, indicating CEACAM5 functions as an essential host receptor for H. pylori T4SS delivery. Genetic introduction of CEACAM1/CEACAM5/CEACAM6 constructs into AZ-521 cells, CagA phosphorylation Western blot, tyrosine dephosphorylation of vinculin/cortactin Cellular microbiology High 30321907
2005 CEACAM5 is required for tumorigenic growth of CX-1 colon carcinoma cells in vivo; antisense-mediated reduction of membrane-bound CEACAM5 significantly diminished subcutaneous tumor growth in nude mice, while cells producing large amounts of secreted (but not membrane-bound) CEACAM5 were not rescued, indicating the membrane-anchored form specifically supports primary tumor growth. Antisense RNA knockdown, xenograft tumor formation assay in nude mice, CEACAM5 expression analysis by ELISA and flow cytometry Cellular & molecular biology letters Medium 12813580
2011 Tumor-associated CEACAM5 (from colon cancer patients) carries high levels of Lewis X and Lewis Y blood-group carbohydrates and elevated branched N-glycans and mannose, and these glycan changes enable recognition by the human C-type lectin DC-SIGN on antigen-presenting cells; Galectin-3 binding also correlated with branched N-glycans on tumor CEACAM5. CEA/MUC1 capture ELISA with plant lectins and human C-type lectins (MGL, DC-SIGN), Galectin-3 binding assay, comparison of matched normal vs. tumor tissue from 48 CRC patients International journal of cancer Medium 21823122
2018 CEACAM5 facilitates breast cancer metastatic outgrowth by promoting mesenchymal-to-epithelial transition (MET); overexpression of CEACAM5 enriched for an epithelial gene expression pattern and facilitated tumor outgrowth at metastatic sites in vivo, with an inverse correlation between CEACAM5 and vimentin expression demonstrated in patient samples. Serial in vivo passaging of lung metastases, high-throughput gain-of-function screen in vivo, transcriptomic profiling, patient tissue immunohistochemistry NPJ breast cancer Medium 29736411
2018 FBW7 suppresses colorectal cancer cell migration by regulating CEACAM5 expression through a HIF1α-dependent mechanism; luciferase and ChIP assays demonstrated CEACAM5 is a direct HIF1α target gene, and FBW7 regulates CEACAM5 in a HIF1α-dependent manner. Luciferase reporter assay, chromatin immunoprecipitation (ChIP), ectopic FBW7 expression, CEACAM5 silencing, migration assay, GEO microarray analysis, IHC of TMA International journal of biological sciences Medium 29910683
2020 ASCL1 (a pioneer transcription factor) drives neuroendocrine reprogramming of prostate cancer associated with increased chromatin accessibility at the CEACAM5 core promoter, leading to increased CEACAM5 expression; this was established using a genetically defined neuroendocrine transdifferentiation assay. Neuroendocrine transdifferentiation assay, chromatin accessibility analysis (ATAC-seq or equivalent), ASCL1 correlation with CEACAM5 expression Clinical cancer research Medium 33199493
2020 CEACAM5 depletion in NSCLC cells inhibited proliferation and migration by activating p38-Smad2/3 signaling, suggesting CEACAM5 suppresses this pathway to promote tumor progression. siRNA knockdown, MTT assay, colony formation, wound healing, immunoblot for p38-Smad2/3, in vivo xenograft The Journal of international medical research Low 32993395
2020 CEACAM5 on tumor cells engages CEACAM1 on NK cells as an inhibitory immune checkpoint, suppressing NK cell cytotoxicity; blocking CEACAM5 with the antibody NEO-201 restored NK-92 cell killing of CEACAM5-positive tumor cell lines in vitro, demonstrating the CEACAM5/CEACAM1 heterophilic interaction as the mechanism. In vitro NK cytotoxicity assay with NK-92 cells, antibody blocking with NEO-201, expression profiling of CEACAM5/NEO-201 on tumor cell lines Cancer biotherapy & radiopharmaceuticals Medium 31928422
2011 Anti-CEACAM5 monoclonal antibody CC4 enhances NK cell cytotoxicity against MHC-I-deficient colorectal cancer cells by blocking the intercellular interaction between epithelial CEACAM5 and the NK inhibitory receptor CEACAM1, thereby relieving CEACAM1-dependent inhibition of NK killing. In vitro NK cytotoxicity assay (ADCC and direct killing), antibody blocking, cell proliferation/migration/aggregation assays PloS one Medium 21731662
2024 CryoEM structure of CEACAM5 A3-B3 domains in complex with the Fab fragment of tusamitamab (anti-CEACAM5 antibody) at 3.11 Å resolution revealed a discontinuous epitope involving residues in both A3 and B3 domains and an N-linked mannose at Asn612; H/D exchange MS identified the paratope (HC residues 101-109, LC residues 48-54 and 88-104); alanine mutagenesis of HC residues 96-108 abolished binding by SPR. Cryo-EM structure determination (3.11 Å), hydrogen/deuterium exchange mass spectrometry, surface plasmon resonance with alanine variants Nature communications High 39477960
2024 Hypoxia-induced CEACAM5 is enriched in exosomes from pancreatic neuroendocrine tumor cells; exosomal CEACAM5 induces M2 polarization of tumor-associated macrophages through activation of the MAPK signaling pathway, and M2-polarized macrophages in turn facilitate pNETs cell migration and invasion. Exosome isolation and characterization, co-culture assays, MAPK pathway activation analysis, macrophage polarization assay, migration/invasion assays FASEB journal Low 38923643
2024 SARS-CoV-2 spike protein induces intestinal barrier dysfunction through interaction between CEACAM5 and Galectin-9; co-IP validated the CEACAM5-Galectin-9 interaction; reduction of CEACAM5 in spike-stimulated enterocytes promoted Galectin-9 expression in CD4+ T cells, leading to inflammatory cytokine release and apoptosis via inhibition of PI3K/AKT/mTOR pathway. Co-immunoprecipitation, molecular docking, mouse spike-Fc injection model, proteomic analysis, KEGG/PPI network analysis, co-culture of CD4+ T cells with Caco-2 cells Frontiers in immunology Low 38686388
2022 CEACAM5 inhibits lymphatic metastasis of head and neck squamous cell carcinoma by inhibiting EMT through reduction of MDM2 expression; CEACAM5 knockdown/overexpression in HNSCC cell lines modulated MDM2 levels, EMT markers, proliferation, and invasion, and a mouse LN metastasis xenograft model confirmed the anti-metastatic role. siRNA knockdown and overexpression in HNSCC cell lines, MDM2 expression analysis, EMT marker Western blot, in vivo mouse LN metastasis model Clinical science Low 36377775
2025 CEACAM5 promotes ferroptosis and autophagy in airway epithelial cells through the JAK/STAT6 pathway, exacerbating asthma; CEACAM5 overexpression in IL-13-stimulated cells activated JAK/STAT6 signaling, which was necessary for CEACAM5-induced ROS accumulation, lipid peroxidation, and ferroptosis; CEACAM5 interference reduced these effects. OVA-sensitized mouse model, IL-13-stimulated Beas-2B cell model, CEACAM5 overexpression and siRNA knockdown, ROS/lipid peroxidation assays, JAK/STAT6 pathway inhibitor Redox report Low 39844719
2005 Antibody Fabs targeting the N-terminal and A1B1 domains of CEACAM5/CEACAM6 (MN-3, MN-15) inhibit tumor cell migration, invasion through extracellular matrix, and adhesion to endothelial cells in vitro, and have antimetastatic effects in vivo in the GW-39 human colonic micrometastasis model; the A3B3-domain-specific MN-14 Fab also reduced adhesion to endothelial cells but not ECM proteins. Migration assay, invasion assay (ECM penetration), adhesion assay (endothelial cells, fibronectin, other ECM proteins), in vivo mouse micrometastasis model with survival endpoint Cancer research Medium 16204051
2025 F. nucleatum surface adhesin CbpF binds CEACAM5 (and CEACAM1) through the EFNGQYQ loop on CbpF and the key Q78 residue of CEACAM5/CEACAM1; structural analysis revealed a Velcro-like multivalent adhesion model enabling CbpF to engage multiple CEACAM1/CEACAM5 molecules simultaneously for dynamic switching between firm anchoring and detachment. Structural determination of CbpF–CEACAM1/CEACAM5 complex, mutagenesis identifying EFNGQYQ loop and Q78 as key contact residues, mechanistic binding studies Proceedings of the National Academy of Sciences of the United States of America High 40928870
2035 CEACAM5 antigen becomes sequestered in intercellular junctions as colorectal cancer (CRC) cell monolayers mature, reducing accessible surface CEACAM5 and causing non-sustained CAR T cell activation (oscillating rather than sustained calcium fluxes); proteolytic disruption of CRC monolayers with trypsin or hyaluronidase treatment increased CEACAM5 accessibility, restored sustained calcium fluxes, and significantly enhanced CAR T cell cytotoxicity and TNF-α secretion. Fluorescence microscopy of CEACAM5 localization and glycocalyx thickness, live-cell calcium flux imaging, cytotoxicity assays with anti-CEACAM5 CAR T cells, local micropipette trypsin/hyaluronidase treatment, human tissue sections Advanced science Medium 41572139
2035 CT109 antibody (dual CEACAM5/CEACAM6 specificity) binds a glycoepitope centered on N309 of CEACAM5/CEACAM6 as determined by scanning mutagenesis; CT109 is internalized by CEACAM5+/CEACAM6+ PDAC cells with a half-life of 2.3 hours. Scanning mutagenesis of the CT109 epitope, immunoblot and flow cytometry for specificity, internalization kinetics assay Current cancer drug targets Medium 38178674
2035 CEACAM5 promoter hypomethylation is a major regulatory mechanism controlling CEA expression in colorectal cancer; treatment with the demethylating agent 5-aza-2'-deoxycytidine enhanced CEACAM5/CEA expression in HCT116 and HT29 cells, and CRC patient samples with elevated serum CEA showed lower average CpG methylation at the CEACAM5 promoter. Critical methylation CpG regions were mapped to -200 to -500 bp and -1000 to -1400 bp upstream of the transcription start site. 5-Aza-dC demethylation treatment, CpG methylation analysis of CEACAM5 promoter, serum CEA measurement in CRC patients, bisulfite sequencing Cancer science Medium 37942534

Source papers

Stage 0 corpus · 74 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2017 The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer immunology, immunotherapy : CII 315 28660319
2007 Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC cancer 207 17201906
2005 Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). Cancer research 176 16204051
2017 Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 90 28817371
2011 Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients. International journal of cancer 86 21823122
2020 Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 77 33199493
2000 Recruitment of CD55 and CD66e brush border-associated glycosylphosphatidylinositol-anchored proteins by members of the Afa/Dr diffusely adhering family of Escherichia coli that infect the human polarized intestinal Caco-2/TC7 cells. Infection and immunity 74 10816511
2022 Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Annals of oncology : official journal of the European Society for Medical Oncology 68 35026412
2020 Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 64 33046521
2020 CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration. The Journal of international medical research 54 32993395
2007 CEACAM5 and CEACAM6 are major target genes for Smad3-mediated TGF-beta signaling. Oncogene 49 17653079
2018 A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis. NPJ breast cancer 45 29736411
2011 A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity. PloS one 37 21731662
2018 Expression of CEACAM1 or CEACAM5 in AZ-521 cells restores the type IV secretion deficiency for translocation of CagA by Helicobacter pylori. Cellular microbiology 35 30321907
2024 Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates. NPJ precision oncology 29 38760413
2021 A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo. Cancer letters 29 34740610
2018 FBW7 suppresses metastasis of colorectal cancer by inhibiting HIF1α/CEACAM5 functional axis. International journal of biological sciences 27 29910683
2023 A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity. Acta pharmacologica Sinica 26 38030799
2019 An Optical Microfiber Biosensor for CEACAM5 Detection in Serum: Sensitization by a Nanosphere Interface. ACS applied materials & interfaces 26 31829549
2013 Characterizing CEACAM5 interaction with CD8α and CD1d in intestinal homeostasis. Mucosal immunology 24 24104458
2018 An efficient constitutive expression system for Anti-CEACAM5 nanobody production in the yeast Pichia pastoris. Protein expression and purification 23 30414968
2023 Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates. Frontiers in oncology 21 36923424
2021 CEACAM5 overexpression is a reliable characteristic of CD133-positive colorectal cancer stem cells. Cancer biomarkers : section A of Disease markers 20 34092615
2023 Identification of a CEACAM5 targeted nanobody for positron emission tomography imaging and near-infrared fluorescence imaging of colorectal cancer. European journal of nuclear medicine and molecular imaging 19 36914753
2024 Hypoxia exosome derived CEACAM5 promotes tumor-associated macrophages M2 polarization to accelerate pancreatic neuroendocrine tumors metastasis via MMP9. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 17 38923643
2023 Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers. Journal of hematology & oncology 17 38087365
2005 Forced expression of deltaN-TCF-1B in colon cancer derived cell lines is accompanied by the induction of CEACAM5/6 and mesothelin. Cancer letters 17 15890249
2024 Phenotypic screen of sixty-eight colorectal cancer cell lines identifies CEACAM6 and CEACAM5 as markers of acid resistance. Proceedings of the National Academy of Sciences of the United States of America 14 38502695
2020 The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway. Cancer biotherapy & radiopharmaceuticals 14 31928422
2022 Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate. Journal of pharmacokinetics and pharmacodynamics 13 35166967
2014 CEACAM5 has different expression patterns in gastric non-neoplastic and neoplastic lesions and cytoplasmic staining is a marker for evaluation of tumor progression in gastric adenocarcinoma. Pathology, research and practice 13 25042385
2020 Heterogeneity of CEACAM5 in breast cancer. Oncotarget 12 33196697
2022 Identification of CEACAM5 as a stemness-related inhibitory immune checkpoint in pancreatic cancer. BMC cancer 11 36494785
2025 Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial. Nature medicine 10 40739424
2023 Detection and clinical significance of CEACAM5 methylation in colorectal cancer patients. Cancer science 10 37942534
2015 Moraxella catarrhalis induces an immune response in the murine lung that is independent of human CEACAM5 expression and long-term smoke exposure. American journal of physiology. Lung cellular and molecular physiology 10 26047639
2024 CEACAM5 and TROP2 define metaplastic and dysplastic transitions in human antral gastric precancerous lesions and tumors. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 9 38221567
2024 CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 9 38782457
2022 Glycoprotein Receptor CEACAM5-Targeted Intraoperative Molecular Imaging Tracer in Non-Small Cell Lung Cancer. The Annals of thoracic surgery 9 35644263
2022 CEACAM5 targeted by miR-498 promotes cell proliferation, migration and epithelial to mesenchymal transition in gastric cancer. Translational oncology 9 35882167
2024 CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells. Current cancer drug targets 8 38178674
2023 Fiber Laser-Based Lasso-Shaped Biosensor for High Precision Detection of Cancer Biomarker-CEACAM5 in Serum. Biosensors 8 37504073
2024 Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody. Frontiers in immunology 6 38720892
2003 The tumorigenic potential of human CX-1 colon adenocarcinoma cells depends on carcinoembryonic antigen (CEACAM5) expression. Cellular & molecular biology letters 6 12813580
2024 Magnetic microspheres enhanced peanut structure cascaded lasso shaped fiber laser biosensor for cancer marker-CEACAM5 detection in serum. Talanta 5 38244308
2024 SARS-Cov-2 spike induces intestinal barrier dysfunction through the interaction between CEACAM5 and Galectin-9. Frontiers in immunology 5 38686388
2024 Structural insights into epitope-paratope interactions of a monoclonal antibody targeting CEACAM5-expressing tumors. Nature communications 5 39477960
2022 Portable Plasmonic Paper-Based Biosensor for Simple and Rapid Indirect Detection of CEACAM5 Biomarker via Metal-Enhanced Fluorescence. International journal of molecular sciences 5 36233297
2022 CEACAM5 inhibits the lymphatic metastasis of head and neck squamous cell carcinoma by regulating epithelial-mesenchymal transition via inhibiting MDM2. Clinical science (London, England : 1979) 5 36377775
2021 CEACAM5, KLK6, SLC35D3, POSTN, and MUC2 mRNA Analysis Improves Detection and Allows Characterization of Tumor Cells in Lymph Nodes of Patients Who Have Colon Cancer. Diseases of the colon and rectum 5 34192710
2025 The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients-The Putative Mechanism Behind ILD. International journal of toxicology 4 39754485
2024 CEA (CEACAM5) expression is common in muscle-invasive urothelial carcinoma of the bladder but unrelated to the disease course. BJUI compass 4 38873357
2023 LncRNA ARAP1-AS1 contributes to lung adenocarcinoma development by targeting miR-8068 to upregulate CEACAM5. Cancer biomarkers : section A of Disease markers 4 37545214
2022 Elevated CEACAM5 Levels in Patients with Asthma. International archives of allergy and immunology 4 35172310
2025 CEACAM5 exacerbates asthma by inducing ferroptosis and autophagy in airway epithelial cells through the JAK/STAT6-dependent pathway. Redox report : communications in free radical research 3 39844719
2025 A high-affinity antibody-drug conjugates Actuximab-MMAE for potent and selective targeting of CEACAM5-Positive tumors. Cancer letters 3 40158720
2025 Development of a novel anti-CEACAM5 VHH for SPECT imaging and potential cancer therapy applications. European journal of nuclear medicine and molecular imaging 3 40358697
2025 Rapid diagnostic imaging and targeted immunotoxin delivery in aggressive prostate cancer using CEACAM5-specific nanobodies. Journal of nanobiotechnology 3 40682047
2025 Binding of Fusobacterium nucleatum autotransporter adhesin CbpF to human CEACAM1 and CEACAM5: A Velcro model for bacterium adhesion. Proceedings of the National Academy of Sciences of the United States of America 2 40928870
2024 Type I Diabetes Mellitus impairs cytotoxic immunity through CEACAM5 upregulation in colorectal cancer : Exploring the intersection of autoimmune dysfunction and cancer progression: the role of NF-κB p65 in colorectal cancer. Journal of molecular histology 2 39419943
2024 Sex-based differences in CEACAM5 expression in lung cancer. Translational cancer research 2 39697744
2020 Molecular Nodal Restaging Based on CEACAM5, FGFR2b and PTPN11 Expression Adds No Relevant Clinical Information in Resected Non-Small Cell Lung Cancer. Journal of investigative surgery : the official journal of the Academy of Surgical Research 2 33342327
2012 Osteopontin's colocalization with the adhesion molecule CEACAM5 in cytoplasm of carcinoma of tongue and its correlation with the invasion of that diease. Cancer cell international 2 22738781
2025 Mutations of the CEACAM5 Gene PELPK Motif in Patients With Appendiceal or Colorectal Adenocarcinoma. In vivo (Athens, Greece) 1 39740861
2025 Targeting CEACAM5: Biomarker Characterization and Fluorescent Probe Labeling for Image-Guided Gastric Cancer Surgery. Biomedicines 1 40868067
2022 Differential expression of carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5) and dipeptidyl peptidase-4 (DPP4) with detection of Middle East respiratory syndrome-coronavirus in peripheral blood. Journal of infection and public health 1 36279687
2026 Enzymatic Remodelling of Tumour Microenvironment Enhances Anti-CEACAM5 CAR T-Cell Efficacy Against Colorectal Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 0 41572139
2025 ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell-Dependent Tumor Immunity and Synergizes with PD-1 Blockade. Cancer immunology research 0 40928366
2025 Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs. mAbs 0 41196029
2025 MiR-5095 inhibits proliferation, migration, and invasion of gastric cancer cells by targeting CEACAM5. Scientific reports 0 41238651
2025 CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB. Antibodies (Basel, Switzerland) 0 41283511
2025 The Landscape of CEACAM5 Expression by Immunohistochemistry in NSCLC. JTO clinical and research reports 0 41584721
2022 Utility of a Highly Specific and Sensitive Podoplanin/D2-40, Calretinin, Thyroid Transcription Factor-1, and Carcinoembryonic Antigen/CD66e Immunohistochemical Panel in Differentiating Malignant Pleural Mesothelioma from Metastatic Adenocarcinoma: An Egyptian Experience. Journal of microscopy and ultrastructure 0 39507645
2019 Platelet Carcinoembryonic Antigen Cell Adhesion Molecule 5 (CEACAM5) as a Possible Novel Diagnostic Tool for Evaluation of Acute Coronary Syndrome. Medical science monitor : international medical journal of experimental and clinical research 0 31865362

Missed literature

Know a paper Affinage missed for CEACAM5? Flag it for the maintainers and the community.

No submissions yet.